Evidence map›Paper›PMID 22204525›Full record

ArticleJournal of biopharmaceutical statistics2012

Power and sample size calculation for microarray studies.

Sin-Ho Jung, S Stanley Young

Abstract readComparative Study
In one paragraph

Article in Journal of biopharmaceutical statistics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Transcriptomic alterations in hypertrophy of the ligamentum flavum: interactions of Rho GTPases, RTK, PIK3, and FGF.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. RNASeqDesign: A framework for RNA-Seq genome-wide power calculation and study design issues.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sin-Ho JungDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA.
S Stanley Young

Funding

Pilot Project for the DTMI CRA ProgramUL1RR024128 · NCRR · DUKE UNIVERSITY · PI CALIFF, ROBERT M · 2006 to 2010
$48.1M
Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSIATIS, ANASTASIOS A · 2010 to 2019
$21.3M
NCI NIH HHS P01 CA142538NCRR NIH HHS 1 UL1 RR024128-01NCRR NIH HHS UL1 RR024128
6 · The paper itself

Abstract

Microarray is a technology to screen a large number of genes to discover those differentially expressed between clinical subtypes or different conditions of human diseases. Gene discovery using microarray data requires adjustment for the large-scale multiplicity of candidate genes. The family-wise error rate (FWER) has been widely chosen as a global type I error rate adjusting for the multiplicity. Typically in microarray data, the expression levels of different genes are correlated because of coexpressing genes and the common experimental conditions shared by the genes on each array. To accurately control the FWER, the statistical testing procedure should appropriately reflect the dependency among the genes. Permutation methods have been used for accurate control of the FWER in analyzing microarray data. It is important to calculate the required sample size at the design stage of a new (confirmatory) microarray study. Because of the high dimensionality and complexity of the correlation structure in microarray data, however, there have been no sample size calculation methods accurately reflecting the true correlation structure of real microarray data. We propose sample size and power calculation methods that are useful when pilot data are available to design a confirmatory experiment. If no pilot data are available, we recommend a two-stage sample size recalculation based on our proposed method using the first stage data as pilot data. The calculated sample sizes are shown to accurately maintain the power through simulations. A real data example is taken to illustrate the proposed method.

Indexed as

Sample SizeHumansOligonucleotide Array Sequence AnalysisPilot Projects

Identifiers

PMID22204525
PMCPMC3324127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.